Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
Novocure (NASDAQ: NVCR) has announced its participation in the upcoming Leerink Global Healthcare Conference scheduled for March 11, 2025. The company's Chief Financial Officer, Christoph Brackmann, will engage in a fireside chat at 4:20 p.m. EST and conduct one-on-one meetings with investors throughout the conference.
Interested parties can access a live audio webcast of the presentation through Novocure's Investor Relations webpage. The recording will remain available for replay for a minimum of 14 days after the event.
Novocure (NASDAQ: NVCR) ha annunciato la sua partecipazione alla prossima Leerink Global Healthcare Conference in programma per l'11 marzo 2025. Il Chief Financial Officer dell'azienda, Christoph Brackmann, parteciperà a una chiacchierata informale alle 16:20 EST e svolgerà incontri individuali con gli investitori durante la conferenza.
Le parti interessate possono accedere a una trasmissione audio in diretta della presentazione attraverso la pagina delle Relazioni con gli Investitori di Novocure. La registrazione rimarrà disponibile per la visione per un minimo di 14 giorni dopo l'evento.
Novocure (NASDAQ: NVCR) ha anunciado su participación en la próxima Leerink Global Healthcare Conference programada para el 11 de marzo de 2025. El Director Financiero de la empresa, Christoph Brackmann, participará en una charla informal a las 4:20 p.m. EST y llevará a cabo reuniones uno a uno con los inversores durante la conferencia.
Las partes interesadas pueden acceder a una transmisión de audio en vivo de la presentación a través de la página de Relaciones con Inversores de Novocure. La grabación estará disponible para su reproducción durante un mínimo de 14 días después del evento.
Novocure (NASDAQ: NVCR)는 2025년 3월 11일에 예정된 Leerink Global Healthcare Conference에 참여한다고 발표했습니다. 회사의 최고재무책임자(CFO)인 Christoph Brackmann은 오후 4시 20분 EST에 화상 대화에 참여하고 회의 동안 투자자와의 일대일 미팅을 진행할 예정입니다.
관심 있는 분들은 Novocure의 투자자 관계 웹페이지를 통해 발표의 실시간 오디오 웹캐스트에 접속할 수 있습니다. 녹음은 행사 후 최소 14일 동안 재생할 수 있습니다.
Novocure (NASDAQ: NVCR) a annoncé sa participation à la prochaine Leerink Global Healthcare Conference prévue pour le 11 mars 2025. Le directeur financier de l'entreprise, Christoph Brackmann, participera à une discussion informelle à 16h20 EST et mènera des réunions individuelles avec des investisseurs tout au long de la conférence.
Les parties intéressées peuvent accéder à un webcast audio en direct de la présentation via la page des Relations Investisseurs de Novocure. L'enregistrement restera disponible en replay pendant un minimum de 14 jours après l'événement.
Novocure (NASDAQ: NVCR) hat seine Teilnahme an der bevorstehenden Leerink Global Healthcare Conference, die für den 11. März 2025 geplant ist, bekannt gegeben. Der Finanzvorstand des Unternehmens, Christoph Brackmann, wird um 16:20 Uhr EST an einem informellen Gespräch teilnehmen und während der Konferenz Einzelgespräche mit Investoren führen.
Interessierte Parteien können über die Investor-Relations-Webseite von Novocure auf eine Live-Audioübertragung der Präsentation zugreifen. Die Aufnahme wird für mindestens 14 Tage nach der Veranstaltung zur Verfügung stehen.
- None.
- None.
BAAR,
A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.
Novocure’s global headquarters is located in Baar,
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304865057/en/
INVESTORS:
Ingrid Goldberg
investorinfo@novocure.com
MEDIA:
Catherine Falcetti
media@novocure.com
Source: Novocure
FAQ
When is Novocure (NVCR) presenting at the Leerink Global Healthcare Conference 2025?
Who will represent NVCR at the Leerink Global Healthcare Conference 2025?
How can investors access Novocure's presentation at the Leerink Conference?
How long will NVCR's Leerink Conference presentation be available for replay?
What type of investor engagement will NVCR offer at the Leerink Healthcare Conference?
